Return to search

Tango Therapeutics nets $60m Series B

Cambridge, Massachusetts-based Tango Therapeutics, a biotechnology company focused on targeted cancer therapies, has secured $60 million in Series B financing.

Cambridge, Massachusetts-based Tango Therapeutics, a biotechnology company focused on targeted cancer therapies, has secured $60 million in Series B financing. Boxer Capital of the Tavistock Group led the round with participation from Cormorant Asset Management and Casdin Capital.

Source: Press Release